読み込み中
Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is based in Salt Lake City, Utah.
前日終値
$1.12
+$0.03 · +2.75%
時間外
$1.12
$0.00 · 0.00%
10月9日 19:02 ET
日中の時刻はETです。市場データは遅延する場合があります。
Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is based in Salt Lake City, Utah.
日中レンジ
現在 $1.12
52週レンジ
現在 $1.12
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
売り
バリュエーション
43
適正価値
センチメント
57
まちまち
リスク
82
極めて高いリスク
モメンタム
16
強い下落
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is based in Salt Lake City, Utah.
日中レンジ
現在 $1.12
52週レンジ
現在 $1.12
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 62.25万 USD | 391.52万 USD | 681.2万 USD | 3421.82万 USD | 9788.56万 USD |
| 売上原価 | 22.24万 USD | 99.91万 USD | 418.49万 USD | 548.11万 USD | 1157.49万 USD |
| 粗利益 | 40.01万 USD | 291.6万 USD | 262.71万 USD | 2873.71万 USD | 8631.07万 USD |
| 研究開発 | 1913.72万 USD | 2097.96万 USD | 2296.26万 USD | 1743.81万 USD | 1496.19万 USD |
| 販売・一般管理 | 1143.94万 USD | 2064.05万 USD | 2114.03万 USD | 2160.76万 USD | 2494.84万 USD |
| 営業費用 | 3168.35万 USD | 4299.73万 USD | 4533.33万 USD | 5571.7万 USD | 4024.57万 USD |
| 受取利息 | 29.29万 USD | 109.18万 USD | 116.19万 USD | 70.4万 USD | 4.56万 USD |
| 減価償却費と償却費 | 110.68万 USD | 137.73万 USD | 123.05万 USD | 128.27万 USD | 33.54万 USD |
| 営業利益 | −3128.34万 USD | −4008.13万 USD | −4270.62万 USD | −2697.98万 USD | 4606.5万 USD |
| 純利益 | −4689.59万 USD | −3763.9万 USD | −3533.29万 USD | −1423.82万 USD | 3665.86万 USD |
会社概要が更新されました 2026年10月10日.
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$180
上昇余地（15971.43%）| 種別 | 発効日 | 詳細 | 基準日 | 支払日 |
|---|---|---|---|---|
株式分割 | 2026年1月2日 | 1:30 | — | — |
発効済み 2026年1月2日
1:30
この株式へのエクスポージャーを報告している上場投資信託です。
AIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
